Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Embolization particles are irregularly-shaped, biocompatible, hydrophilic, non-resorbable particles. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Embolization particles are used for the embolization of arteriovenous malformations and hyper vascularized tumors, including symptomatic uterine fibroids. It is a minimally invasive therapy used in many procedures as a part of interventional radiology. Embolization is used to stop bleeding as well as to treat tumors that cannot be removed by surgery by stopping its blood supply. This report studies the global market for embolization particle in terms of revenue (USD million) from 2019 to 2024.
The global embolization particle market has gained profitable growth owing increasing demand of embolization particles for interventional radiology and interventional cardiovascular procedure. The market is further boosted by technological advancements in embolization particles and increasing preference for minimally invasive procedures. Moreover, the market is expected to show robust growth during the forecast period due to surging government spending on pharmaceutical R&D in emerging nations. recent advances in microsphere technologies and favourable reimbursement scenario are further expected to propel this market growth. However, the global embolization particle market is hindered by scarcity of interventional neuroradiologists and interventional neuroradiology (INR) labs, strict regulations and risks such as coagulation of vital veins & blood supply.
The report analyses the global embolization particle market, based on product type, application, end user and geography.
The market is segmented into various product type, which includes radioembolization particles, microspheres, drug-eluting beads and others. Among these, the radioembolization particles segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to its use in the treatment of cancer.
The embolization particle finds applications into peripheral vascular disease, neurology, oncology, urology and others. In 2017, the oncology application dominated the global market, owing to increasing use of embolization particle in cancer treatments. Radioembolization is a cancer treatment in which radioactive particles are delivered to a tumor through the bloodstream. The particles lodge in the tumor and emit radiation that kills cancer cells.
The market is segmented into various end users, which includes hospitals, ambulatory surgical centres and clinics. Among these, the hospitals segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to surging number of hospitals using embolization particle for various treatments.
By geography, the global embolization particle market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America dominated the global embolization particle market in 2017, due to advanced hospitals infrastructures, and availability of skilled healthcare professionals. Presence of strong economic condition and huge development in the healthcare domain are further fuelling the market growth. Moreover, Asia Pacific is the anticipated to grow at a fastest growth rate during the forecast period 2019 to 2024 among other regions. The higher rate of the growth is fuelled by increasing emphasis on rapid diagnosis and treatment of cancer, changing lifestyle and increasing prevalence of cancer among geriatric population.
The demand for embolization particle market is gauzed by market attractiveness tool and company market share. The key players of global embolization particle market include Sirtex Medical, Merit Medical, Cook Medical, BTG Medical, Boston Scientific Corporation, Terumo Corporation, HENGRUI Medical, Interface Biomaterials B.V. and Alicon among others. Strategies such as product innovation and collaborations are adopted by global players as well as regional players, to maintain the product superiority, thus interpreting market sustainability.
The global embolization particle market is segmented based on product type, application, end users and geography. The market is segmented into various product type, which includes radioembolization particles, microspheres, drug-eluting beads and others. Among these, the radioembolization particles segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to its use in the treatment of cancer. The embolization particle market finds applications into peripheral vascular disease, neurology, oncology, urology and others. In 2017, the oncology application dominated the global market, owing to increasing use of embolization particle in cancer treatments. Radioembolization is a cancer treatment in which radioactive particles are delivered to a tumor through the bloodstream. The particles lodge in the tumor and emit radiation that kills cancer cells. The market is segmented into various end users, which includes hospitals, ambulatory surgical centres and clinics. Among these, the hospitals segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to surging number of hospitals using embolization particle for various treatments. By geography, the global embolization particle market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America dominated the global embolization particle market in 2017, due to advanced hospitals infrastructures, and availability of skilled healthcare professionals.
Why to buy this report:
